Literature DB >> 7768962

Cytotoxicity of ether phospholipid BM 41.440 on neuroblastoma cells.

R Girgert1, P Schweizer, I Bock, R Narr, G Bruchelt.   

Abstract

The thioether lysophospholipid BM 41.440 proved to be toxic against cells of two neuroblastoma cell lines in a dose- and time-dependent manner. The ID50 estimated in three different in vitro test systems declined from about 10 micrograms/ml after 24 h to 1 microgram/ml after a 1-week treatment of the neuroblastoma cells. These values are comparable to the ID50 found for neoplastic cells derived from other tissues. In comparison, hematopoietic progenitor cells (granulocyte/monocyte-colony-forming units) proved to be less sensitive to short-term treatment with BM 41.440. After long exposure to this drug the selectivity towards neuroblastoma cells decreased. This observation makes it unlikely that BM 41.440 can be used for treatment of neoplasia such as neuroblastoma, because only short-term treatment is acceptable considering the high bone marrow toxicity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7768962     DOI: 10.1007/BF01209591

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  12 in total

1.  Inhibition of protein kinase C, (sodium plus potassium)-activated adenosine triphosphatase, and sodium pump by synthetic phospholipid analogues.

Authors:  B Zheng; K Oishi; M Shoji; H Eibl; W E Berdel; J Hajdu; W R Vogler; J F Kuo
Journal:  Cancer Res       Date:  1990-05-15       Impact factor: 12.701

2.  Effects of thioether phospholipid BM 41.440 on protein kinase C and phorbol ester-induced differentiation of human leukemia HL60 and KG-1 cells.

Authors:  M Shoji; R L Raynor; W E Berdel; W R Vogler; J F Kuo
Journal:  Cancer Res       Date:  1988-12-01       Impact factor: 12.701

3.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

4.  Cytotoxicity of thioether-lysophospholipids in leukemias and tumors of human origin.

Authors:  W E Berdel; M Fromm; U Fink; W Pahlke; U Bicker; A Reichert; J Rastetter
Journal:  Cancer Res       Date:  1983-11       Impact factor: 12.701

5.  Destruction of human solid tumors by alkyl lysophospholipids.

Authors:  M H Runge; R Andreesen; A Pfleiderer; P G Munder
Journal:  J Natl Cancer Inst       Date:  1980-06       Impact factor: 13.506

6.  Treatment results of the thioether lipid ilmofosine in patients with malignant tumours.

Authors:  M Winkelmann; K Ebeling; G Strohmeyer; G Hottenrott; Z Mechl; W Berges; T Scholten; M Westerhausen; G Schlimok; R Sterz
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

7.  Antineoplastic activity of the thioether lysophospholipid derivative BM 41.440 in vitro.

Authors:  M Fromm; W E Berdel; H D Schick; U Fink; W Pahlke; U Bicker; A Reichert; J Rastetter
Journal:  Lipids       Date:  1987-11       Impact factor: 1.880

8.  Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs.

Authors:  S E Salmon; A W Hamburger; B Soehnlen; B G Durie; D S Alberts; T E Moon
Journal:  N Engl J Med       Date:  1978-06-15       Impact factor: 91.245

9.  Cytotoxicity and metabolism of alkyl phospholipid analogues in neoplastic cells.

Authors:  D R Hoffman; L H Hoffman; F Snyder
Journal:  Cancer Res       Date:  1986-11       Impact factor: 12.701

10.  Modulation of chemical carcinogenesis in rats by alkyl lysophospholipids.

Authors:  M R Berger; D Schmähl
Journal:  Lipids       Date:  1987-11       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.